AtriCure (ATRC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic vision and growth targets

• Aiming to reach $1 billion in revenue by 2030, driven by double-digit growth and market expansion in arrhythmia management and pain management segments.

• Holds over 90% market share in core arrhythmia management, with ongoing efforts to expand into under-penetrated markets.

• Major clinical trials like BoxX-NoAF and LeAAPS are expected to significantly expand the addressable market and drive future growth.

• Pain management business is expanding beyond thoracotomies into amputations, targeting additional multi-billion-dollar opportunities.

• Profitability has been achieved, enabling self-sustained investment in growth and innovation without reliance on external funding.

Competitive landscape and innovation

• Maintains a proactive approach to competition by investing 18%-20% of revenue in R&D, focusing on continuous product innovation and robust clinical evidence.

• Clinical data and next-generation products create a strong competitive moat, with the FLEX-Mini Clip now representing over 40% of revenue.

• Views new entrants as validation of market potential, with historical examples showing that competition can expand the overall market.

• Team expertise and long-standing customer relationships are key differentiators in maintaining market leadership.

• Strategic investments are made for long-term growth rather than as reactionary measures to competition.

Product pipeline and clinical milestones

• BoxX-NoAF trial enrollment accelerated, with initial 30-day data expected soon and three-year follow-up planned.

• LeAAPS trial data anticipated in a similar timeframe, both expected to multiply market opportunities in cardiac surgery.

• New AtriClip device for open chest procedures planned for launch next year, with ongoing optimization of pain management devices for new surgical applications.

• Expansion into additional surgical procedures is expected over the next few years.